Increased plasma level of kynurenic acid in drug-free patients with first-episode schizophrenia compared to patients with chronic schizophrenia and healthy controls: preliminary data

References

• Plitman E, Iwata Y, Caravaggio F, et al. Kynurenic acid in schizophrenia: a systematic review and meta-analysis. Schizophr Bull. 2017;43(4):764–777.
   PubMed Web of Science ®Google Scholar
• Guillemin GJ, Kerr SJ, Smythe GA, et al. Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection. J Neurochem. 2001;78(4):842–853.
   PubMed Web of Science ®Google Scholar
• Tuboly G, Tar L, Bohar Z, et al. The inimitable kynurenic acid: the roles of different ionotropic receptors in the action of kynurenic acid at a spinal level. Brain Res Bull. 2015;112:52–60.
   PubMed Web of Science ®Google Scholar
• Hilmas C, Pereira EF, Alkondon M, et al. The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications. J Neurosci. 2001;21(19):7463–7473.
   PubMed Web of Science ®Google Scholar
• Terry AV Jr., Callahan PM. α7 nicotinic acetylcholine receptors as therapeutic targets in schizophrenia: update on animal and clinical studies and strategies for the future. Neuropharmacology. 2020;170:108053.
   PubMed Web of Science ®Google Scholar
• Rowland LM, Bustillo JR, Mullins PG, et al. Effects of ketamine on anterior cingulate glutamate metabolism in healthy humans: a 4-T proton MRS study. AJP. 2005;162(2):394–396.
   Google Scholar
• Thiebes S, Leicht G, Curic S, et al. Glutamatergic deficit and schizophrenia-like negative symptoms: new evidence from ketamine-induced mismatch negativity alterations in healthy male humans. J Psychiatry Neurosci. 2017;42(4):273–283.
   PubMed Web of Science ®Google Scholar
• Cadinu D, Grayson B, Podda G, et al. NMDA receptor antagonist rodent models for cognition in schizophrenia and identification of novel drug treatments, an update. Neuropharmacology. 2018;142:41–62.
   PubMed Web of Science ®Google Scholar
• Zick JL, Blackman RK, Crowe DA, et al. Blocking NMDAR disrupts spike timing and decouples monkey prefrontal circuits: implications for activity-dependent disconnection in schizophrenia. Neuron. 2018;98(6):1243–1255.e1245.
   PubMed Web of Science ®Google Scholar
• Kindler J, Lim CK, Weickert CS, et al. Dysregulation of kynurenine metabolism is related to proinflammatory cytokines, attention, and prefrontal cortex volume in schizophrenia. Mol Psychiatry. 2020;25(11):2860–2872.
   PubMed Web of Science ®Google Scholar
• Linderholm KR, Skogh E, Olsson SK, et al. Increased levels of kynurenine and kynurenic acid in the CSF of patients with schizophrenia. Schizophr Bull. 2012;38(3):426–432.
   PubMed Web of Science ®Google Scholar
• Nilsson LK, Linderholm KR, Engberg G, et al. Elevated levels of kynurenic acid in the cerebrospinal fluid of male patients with schizophrenia. Schizophr Res. 2005;80(2–3):315–322.
   PubMed Web of Science ®Google Scholar
• Erhardt S, Schwieler L, Emanuelsson C, et al. Endogenous kynurenic acid disrupts prepulse inhibition. Biol Psychiatry. 2004;56(4):255–260.
   PubMed Web of Science ®Google Scholar
• Kozak R, Campbell BM, Strick CA, et al. Reduction of brain kynurenic acid improves cognitive function. J Neurosci. 2014;34(32):10592–10602.
   PubMed Web of Science ®Google Scholar
• Huang X, Ding W, Wu F, et al. Increased plasma kynurenic acid levels are associated with impaired attention/vigilance and social cognition in patients with schizophrenia. NDT. 2020;16:263–271.
   Google Scholar
• Myint AM, Schwarz MJ, Verkerk R, et al. Reversal of imbalance between kynurenic acid and 3-hydroxykynurenine by antipsychotics in medication-naive and medication-free schizophrenic patients. Brain Behav Immun. 2011;25(8):1576–1581.
   PubMed Web of Science ®Google Scholar
• Fukushima T, Iizuka H, Yokota A, et al. Quantitative analyses of schizophrenia-associated metabolites in serum: serum D-lactate levels are negatively correlated with gamma-glutamylcysteine in medicated schizophrenia patients. PLOS One. 2014;9(7):e101652.
   PubMed Web of Science ®Google Scholar
• Fazio F, Lionetto L, Curto M, et al. Xanthurenic acid activates mglu2/3 metabotropic glutamate receptors and is a potential trait marker for schizophrenia. Sci Rep. 2015;5:17799.
   PubMed Web of Science ®Google Scholar
• Ceresoli-Borroni G, Rassoulpour A, Wu HQ, et al. Chronic neuroleptic treatment reduces endogenous kynurenic acid levels in rat brain. J Neural Transm. 2006;113(10):1355–1365.
   PubMed Web of Science ®Google Scholar
• Larsson MK, Schwieler L, Goiny M, et al. Chronic antipsychotic treatment in the rat – effects on brain interleukin-8 and kynurenic acid. Int J Tryptophan Res. 2015;8:49–52.
   PubMed Web of Science ®Google Scholar
• Sathyasaikumar KV, Stachowski EK, Wonodi I, et al. Impaired kynurenine pathway metabolism in the prefrontal cortex of individuals with schizophrenia. Schizophr Bull. 2011;37(6):1147–1156.
   PubMed Web of Science ®Google Scholar
• De Picker L, Fransen E, Coppens V, et al. Immune and neuroendocrine trait and state markers in psychotic illness: decreased kynurenines marking psychotic exacerbations. Front Immunol. 2020;10:2971.
   PubMed Web of Science ®Google Scholar
• Nock B, Rajpara A, O'Connor LH, et al. Autoradiography of [3h] u-69593 binding sites in rat brain: evidence for kappa opioid receptor subtypes. Eur J Pharmacol. 1988;154(1):27–34.
   PubMed Web of Science ®Google Scholar
• Grattan RE, Linscott RJ. Components of schizophrenia liability affect the growth of psychological stress sensitivity following major life events. Schizophr Res. 2019;212:134–139.
   PubMed Web of Science ®Google Scholar
• Chiappelli J, Pocivavsek A, Nugent KL, et al. Stress-induced increase in kynurenic acid as a potential biomarker for patients with schizophrenia and distress intolerance. JAMA Psychiatry. 2014;71(7):761–768.
   PubMed Web of Science ®Google Scholar
• Beggiato S, Ieraci A, Tomasini MC, et al. Prenatal THC exposure raises kynurenic acid levels in the prefrontal cortex of adult rats. Prog Neuropsychopharmacol Biol Psychiatry. 2020;100:109883.
   PubMed Web of Science ®Google Scholar
• Moller M, Du Preez JL, Emsley R, et al. Social isolation rearing in rats alters plasma tryptophan metabolism and is reversed by sub-chronic clozapine treatment. Neuropharmacology. 2012;62(8):2499–2506.
   PubMed Web of Science ®Google Scholar
• MacDowell KS, Munarriz-Cuezva E, Meana JJ, et al. Paliperidone reversion of maternal immune activation-induced changes on brain serotonin and kynurenine pathways. Front Pharmacol. 2021;12:682602.
   PubMed Web of Science ®Google Scholar
• Chiappelli J, Notarangelo FM, Pocivavsek A, et al. Influence of plasma cytokines on kynurenine and kynurenic acid in schizophrenia. Neuropsychopharmacol. 2018;43(8):1675–1680.
   PubMed Web of Science ®Google Scholar
• Szymona K, Zdzisińska B, Karakuła-Juchnowicz H, et al. Correlations of kynurenic acid, 3-hydroxykynurenine, sIL-2R, IFN-alpha, and IL-4 with clinical symptoms during acute relapse of schizophrenia. Neurotox Res. 2017;32(1):17–26.
   PubMed Web of Science ®Google Scholar
• Favennec M, Hennart B, Caiazzo R, et al. Erratum: the kynurenine pathway is activated in human obesity and shifted toward kynurenine monooxygenase activation. Obesity. 2016;24(8):1821.
   PubMed Web of Science ®Google Scholar
• Jayawickrama GS, Sadig RR, Sun G, et al. Kynurenine aminotransferases and the prospects of inhibitors for the treatment of schizophrenia. Curr Med Chem. 2015;22(24):2902–2918.
   PubMed Web of Science ®Google Scholar
• Noyan H, Erdağ E, Tüzün E, et al. Association of the kynurenine pathway metabolites with clinical, cognitive features and IL-1beta levels in patients with schizophrenia spectrum disorder and their siblings. Schizophr Res. 2021;229:27–37.
   PubMed Web of Science ®Google Scholar
• Huang J, Tong J, Zhang P, et al. Effects of neuroactive metabolites of the tryptophan pathway on working memory and cortical thickness in schizophrenia. Transl Psychiatry. 2021;11(1):198.
   PubMed Web of Science ®Google Scholar
• Cathomas F, Guetter K, Seifritz E, et al. Quinolinic acid is associated with cognitive deficits in schizophrenia but not major depressive disorder. Sci Rep. 2021;11(1):9992.
   PubMed Web of Science ®Google Scholar